Patricia Davis (Patty)

Vice President Clinical Operations at Neurotech Pharmaceuticals, Inc.

Patricia (Patty) Davis has a diverse work experience spanning multiple roles and companies. Patricia (Patty) is currently working at Neurotech Pharmaceuticals, Inc. as the Vice President Clinical Operations. Prior to that, they held the position of Sr. Director Clinical Operations at both Neurotech Pharmaceuticals, Inc. and Agenus. Patricia (Patty) also worked as a Sr. Consultant and Lead Consultant, Organizational Solutions at Halloran Consulting Group, Inc. In addition, they have experience at MedSource as a Project Manager, Associate Project Manager, Lead CRA, and Sr. CRA. Patricia (Patty) also worked as a Clinical Research Consultant while being self-employed. At SCRI (Clinical Operations), they held the role of Sr. Manager, Site Services, overseeing Protocol Education, Regulatory, and Study Activation. Earlier in their career, they worked as a Clinical Project Lead at SCRI (Development Innovations) and held various roles in regulatory affairs and site operations support at SCRI. Patricia (Patty) started their career at New South Medical as an Executive Office Manager/Clinical Research Project Site Manager/GYN Nurse/Billing Specialist, and also worked as a Contract Licensed Practical Nurse at Excell Medical Staffing.

Patricia (Patty) Davis pursued their education in the field of Practical Nursing from 1999 to 2000 at the Tennessee Technology Center. During this time, they successfully completed their LPN degree.

Location

Nashville, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients. Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don't have another treatment option. Our goal is to help these patients sustain their quality of life.


Industries

Employees

11-50

Links